Sitasliptin. Type 2 diabetes: Limited efficacy, too many unknown risks

Prescrire International

Volumn 17, Issue 93, 2008, Pages 12-15

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYTOCHROME P450; GLIBENCLAMIDE; GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INCRETIN; METFORMIN; PIOGLITAZONE; SEROTONIN RECEPTOR; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CREATININE BLOOD LEVEL; DEPRESSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; SIDE EFFECT; TERATOGENICITY; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; DRUG COMBINATION; DRUG EFFECT; EUROPE;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; EUROPE; GLIPIZIDE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PYRAZINES; TRIAZOLES;

EID: 38849110072     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Prescrire Rédaction "Différentes familles d'antidiabétiques" Rev Prescrire 2007; 27 (285):487.
2. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: 21-995 - Approved labelling" undated: 13 pages.
3. Prescrire Editorial Staff "Rosiglitazone and pioglitazone" Prescrire Int 2002; 11 (62): 170-176.
4. Prescrire Editorial Staff "Insuline in type 2 diabetes" Prescrire Int 2005; 14 (79): 187-193.
5. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: 21-995 Medical review" 31 August 2006: 214 pages.
6. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number 21-995 Statistical review" 18 September 2006: 49 pages.
7. Scott R et al. "Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes" Int J Clin Pract 2007; 61 (1): 171-180.
8. Raz I et al. "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus" Diabetologia 2006; 49 (11): 2564-2571.
9. European Medicines Agency - CHMP "European Public Assessment Report (first version) - Januvia Scientific discussion": 39 pages; posted on EMEA website 21 March 2007.
10. Commission of the European Communities "Summary of Product Characteristics Januvia 25 mg" 21 March 2007: 31 pages.
11. Nauck MA et al. "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized double-blind, non-inferiority trial" Diabetes Obes Metal 2007; 9(2): 194-205.
12. Rosenstock J et al. "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study" Clin Ther 2006; 28 (10): 1556-1568.
13. Charbonnel B et al. "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone" Diabetes Care 2006; 29 (12): 2638-2643.
14. Goldstein BJ et al. "Efficacy of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes" Diabetes Care 2007; 30: 1979-1987.
15. o. Diabète de type 2: pour quelques patients en surpoids" Rev Prescrire 2007; 27 (285): 485-489.
16. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: 21-995 Statistical review" Carcinogenicity study" 16 May 2006: 48 pages.
17. Prescrire Editorial Staff "Avoid prescribing glitazones to diabetes patients, either alone or in combination" Prescrire Int 2007; 16 (90): 145.